Cancer-associated bone disease

  title={Cancer-associated bone disease},
  author={Ren{\'e} Rizzoli and J. J. Body and M.-L. Brandi and Jorge Benito Cannata-And{\'i}a and Daniel Chappard and Abdellah El Maghraoui and Claus C. Gl{\"u}er and Dorota Kendler and Nicola Napoli and Alexandra Papaioannou and Dominique D Pierroz and Maya Rahme and Catherine H. Van Poznak and Tobias Johannes de Villiers and G. El Hajj Fuleihan},
  journal={Osteoporosis International},
Bone is commonly affected in cancer. Cancer-induced bone disease results from the primary disease, or from therapies against the primary condition, causing bone fragility. Bone-modifying agents, such as bisphosphonates and denosumab, are efficacious in preventing and delaying cancer-related bone disease. With evidence-based care pathways, guidelines assist physicians in clinical decision-making. Of the 57 million deaths in 2008 worldwide, almost two thirds were due to non-communicable diseases… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS